Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 41

  • 849 clinical trials
  • 267 recruiting
  • 359 conditions
  • 25 countries

Conditions in this area

359 conditions with trials, the busiest first

Dermatitis atopic89Malignant melanoma79Systemic lupus erythematosus63Psoriasis54Hidradenitis47Psoriatic arthropathy46Systemic scleroderma40Metastatic malignant melanoma32Vitiligo24Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis16Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Basal cell carcinoma12Diabetic foot12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+335

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

849 clinical trials

Hidradenitis

Not recruiting

Efficacy and Safety Evaluation of Tulisokibart in Moderate to Severe Hidradenitis Suppurativa: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Systemic lupus erythematosus

Not recruiting

Evaluation of safety and efficacy of 19CP02 combined with cyclophosphamide and fludarabine phosphate in adults with treatment‑refractory active systemic lupus erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Galapagos

Systemic lupus erythematosus+1

Not recruiting

Evaluation of Long-term Safety and Efficacy of Enpatoran in Subacute Cutaneous, Discoid, and Systemic Lupus Erythematosus Post-WILLOW Study Completion

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran
  • Sponsor:Merck Healthcare KGaA

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Nonbiologic Standard of Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Psoriasis

Not recruiting

A study to examine how the body processes and removes DC-806 in healthy male volunteers

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:DC-806
  • Sponsor:DICE Therapeutics Inc.

Dermatitis atopic

Not recruiting

Safety and Tolerability of Topical Iodine (DLQ03) in Patients with Mild to Moderate Atopic Dermatitis Colonized with Staphylococcus aureus

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Dermaliq Therapeutics Inc.

Androgenetic alopecia

Not recruiting

Bioavailability Study of Oral Minoxidil 1 mg Tablet Compared with Topical Minoxidil Solution in Healthy Volunteers with Androgenetic Alopecia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · Healthy volunteers
  • Substances:Minoxidil
  • Sponsor:Industrial Farmaceutica Cantabria S.A.

Eosinophilic oesophagitis+3

Not recruiting

Pharmacokinetics and Safety of Single Oral Etrasimod Arginine in Healthy Adults for Ulcerative Colitis Using At-Home Tasso Sampling and Wearable Monitoring

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Etrasimod Arginine
  • Sponsor:Pfizer Inc.

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Muscle strain+3

Not recruiting

Study of Esflurbiprofen Hydrogel Patch Adhesion in Healthy Volunteers

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Esflurbiprofen
  • Sponsor:Teikoku Seiyaku Co. Ltd.

Multiple sclerosis+1

Not recruiting

Phase 1 study of remibrutinib exposure in cerebrospinal fluid after oral dosing in healthy participants

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

A study testing TRIV-509 compared to placebo in adults with moderate to severe atopic dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG1 BISPECIFIC MONOCLONAL ANTIBODY AGAINST KALLIKREIN-5 AND KALLIKREIN-7
  • Sponsor:Triveni Bio Inc.

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.